XBiotech (XBIT) FCF Margin (2020 - 2022)

XBiotech (XBIT) posted quarterly FCF Margin of 909.67% for Q4 2022, down 962.02% quarter-over-quarter from 85.65% in Q3 2022.

XBiotech (XBIT) FCF Margin (2020 - 2022) Analysis & Trends

XBiotech's FCF Margin history runs 3 years deep, the most recent figure standing at 909.67% for Q4 2022.

In Q4 2022, FCF Margin changed N/A year-over-year to 909.67%; the TTM figure through Sep 2023 stood at 6089.33% (down 595668.0% YoY), while the FY2022 annual figure was 370.12%, down 74716.0% from the prior year.
FCF Margin for Q4 2022 stood at 909.67%, down from 85.65% in the prior quarter.
The five-year high for FCF Margin was 1560.31% in Q2 2021, with the low at 1037.6% in Q1 2022.
The 3-year median for FCF Margin is 85.65% (2022), against an average of 125.16%.
The sharpest annual moves came in 2021 and 2022: FCF Margin soared 163474 bps in 2021, then sank 191887 bps in 2022.
XBiotech's FCF Margin stood at 7.62% in 2020, then plunged by 1291 bps to 90.77% in 2021, then tumbled by 902 bps to 909.67% in 2022.
Business Quant data shows XBIT's FCF Margin at 909.67% in Q4 2022, 85.65% in Q3 2022, and 358.56% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	XBiotech	68.90 Mn	68.90 Mn	-	-

Download Data